GRAL
GRAL
NASDAQ · Biotechnology

Grail Inc

$120.80
-22.86 (-15.91%)
As of Nov 5, 8:26 PM ET ·
Financial Highlights (FY 2026)
Revenue
166.58M
Net Income
-462,202,391
Gross Margin
48.5%
Profit Margin
-277.5%
Rev Growth
+38.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.5% 48.5% 65.8% 65.8%
Operating Margin -382.0% -343.8% 9.2% 8.6%
Profit Margin -277.5% -263.6% 7.6% 7.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 166.58M 120.39M 2.02B 1.78B
Gross Profit 80.73M 58.34M 1.33B 1.17B
Operating Income -636,305,702 -413,872,321 184.76M 152.85M
Net Income -462,202,391 -300,630,304 154.03M 135.92M
Gross Margin 48.5% 48.5% 65.8% 65.8%
Operating Margin -382.0% -343.8% 9.2% 8.6%
Profit Margin -277.5% -263.6% 7.6% 7.7%
Rev Growth +38.4% +38.4% +15.5% +5.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.78B 1.62B
Total Equity — — 1.86B 2.14B
D/E Ratio — — 0.96 0.76
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -473,039,322 -324,772,245 214.07M 192.49M
Free Cash Flow — — 137.52M 156.47M